In addition to testing the effectiveness of new treatments through clinical trials, physicians and scientists here also conduct long-term cohort studies and research in the lab. With close cooperation between research and patient care activities, discoveries made in the lab can be translated into clinical advances that may improve treatment options for neuroblastoma.
Our physician-scientists currently are investigating:
In addition, Susan Cohn, MD, serves as co-chair of the International Neuroblastoma Risk Group (INRG) task force – a group of pediatric oncologists dedicated to transforming neuroblastoma research and clinical care. Under her leadership, Samuel Volchenboum, MD, PhD, MS, and other neuroblastoma experts are working to develop an interactive database. This database allows researchers across institutions -- and continents -- to share clinical trial outcomes. It also includes demographic information collected by the INRG, as well as biobank and genomic data collected from around the world. The result is a tool that provides an international risk classification system and helps to advance treatment options for all patients with neuroblastoma.